Research programme: Huntington's disease gene therapy - Regeneron Pharmaceuticals

Drug Profile

Research programme: Huntington's disease gene therapy - Regeneron Pharmaceuticals

Alternative Names: AdBDNF/Noggin; Huntington's disease gene therapy

Latest Information Update: 02 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornell University; Regeneron Pharmaceuticals; University of Rochester
  • Developer Regeneron Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Brain-derived neurotrophic factor expression stimulants; Gene transference; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Huntington's disease

Most Recent Events

  • 21 Oct 2009 Pharmacodynamics data from a preclinical trial in Huntington's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 07 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Parkinson's Disease and Movement Disorders pharmacodynamics section
  • 10 Jun 2005 Preclinical trials in Huntington's disease in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top